The Call BeOne Medicines Bulls Got Right

If you only glanced at headlines about patent cliffs, pricing pressure, and BeOne Medicines’ dependence on BRUKINSA, this period might look like one long risk warning rather than an opportunity. Investors who held BeOne Medicines from the start of the year are up 36.3%, including dividends. If you were deciding on 1 January whether to commit fresh capital, how could the same public record support both that anxiety and this outcome?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

BeOne Medicines has already moved. Pinpoint other ways to investigate the theme among 36 healthcare AI stocks.

The Two Stories Investors Were Arguing About On BeOne Medicines

The shares cost US$304 at the start of the period, which left investors weighing two very different stories about BeOne Medicines.

The bullish narrative pointed to a Fair Value of US$486, or about 60% above the start price. It relied on expectations of 28.1% annual revenue growth and a shift from a loss to a 27.7% profit margin within three years.

The bearish view focused on a Fair Value of US$250, about 18% below the start price. That case assumed much slower 5.0% annual revenue growth, a modest 3.6% profit margin, and pressure from patent cliffs and pricing controls on BRUKINSA.

What The Evidence Did To The BeOne Medicines Argument

The clearest test came from Q3 2026, when BeOne Medicines reported revenue of US$1.89b and net income of US$384.7m, with net margin at 20.4% compared with 8.8% a year earlier. That profitability level moved closer to the bullish margin story, although reliance on BRUKINSA and pricing risk still kept the cautious thesis alive. Overall, the evidence cut both ways.

The lesson carries across. When a forecast rests on margins expanding, track reported net margin against that target each quarter and weigh any single-drug dependence against it before updating your view.

What BeOne Medicines' Price Already Assumes After A 36% Run

BeOne Medicines now trades at US$424 from the start of the year, with this bearish analyst Narrative on Simply Wall St placing its Fair Value below that level.

The Narrative focuses on BRUKINSA dependence, high 80% gross margins and rising operating spend. A buyer today effectively assumes oncology expansion justifies the current multiple. How does the risk of sustained mid teens cost growth compare with that pipeline exposure for you?

"The main requirement for the strategy to work is that BRUKINSA retains its leadership position while BeOne scales a broader oncology portfolio, including the late stage solid tumor and B cell malignancy regimens, without letting mid teens operating expense growth erode the benefit of gross margins in the high 80% range."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Looking Beyond BeOne Medicines

BeOne Medicines gives you one version of the oncology story. There is also a different way to think about the same need.

While BeOne focuses on a single flagship therapy, another drug maker is advancing a wider range of cancer treatments. It is also pushing into heart health, vaccines and infectious disease.

The common thread is simple. Patients and doctors want more options, longer treatment durability and easier dosing schedules.

One firm is pursuing that through a concentrated portfolio. The other is relying on a broader late stage pipeline and new modalities, creating a different set of trade offs for your watchlist.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 26% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com